Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyLife: EC-MPS Switch in Renal Transplant
NCT00149968Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection, sponsored by Novartis. Primary endpoint: Changes in gastrointestinal symptom severity after conversion from MMF to enteric-coated mycophenolate sodium. Started Apr 2005; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00149968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149968.